Core Insights - The presentation is focused on data from the company's program referred to as 989, which is significant for its implications in treating patients with essential thrombocythemia (ET) and myelofibrosis (MF) [1] Group 1: Presentation Context - The presentation was delayed due to adherence to ASH guidelines and the availability of speakers who were presenting scientific data at the meeting [1] - The session is expected to last approximately 45 minutes, during which the company will review data related to the 989 program [1] Group 2: Data Significance - Some of the data being discussed was previously presented in June at the AHA conference, indicating ongoing research and development efforts [1] - The company emphasizes the importance of the translational data and its relevance to the treatment of MF, highlighting the potential impact of their research [1]